Recombinant IL2RA (Basiliximab Biosimilar) antibody

Catalog No. ABIN5668050

This Human Chimeric antibody specifically detects IL2RA (Basiliximab Biosimilar) in FACS, BR, IF, IHC and WB. It exhibits reactivity toward Human, Cynomolgus and Rhesus Monkey.

Quick Overview for Recombinant IL2RA (Basiliximab Biosimilar) antibody (ABIN5668050)

Target: IL2RA (Basiliximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human, Cynomolgus, Rhesus Monkey

Host: Human

Clonality: Chimeric

Conjugate: This IL2RA (Basiliximab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), Blocking Reagent (BR), Immunofluorescence (IF), Immunohistochemistry (IHC), Western Blotting (WB)

Product Details anti-IL2RA (Basiliximab Biosimilar) Antibody

Purpose: Anti-IL-2R alpha (CD25) [Basiliximab], Human IgG1, kappa

Specificity: Basiliximab recognises the human IL-2R and binds to the epitope (116)ERIYHFV(122) within the extracellular domain of the CD25 subunit - binding is abolished when 2 or more residues within the epitope are mutated. This epitope overlaps with the interaction site of CD25 and IL-2. CD25 is found in the high-affinity IL-2R (αβγc) - T cells only express CD25 upon activation. IL-2 binding to IL-2R on T cells modulates proliferation and differentiation.

Cross-Reactivity: Cynomolgus, Rhesus Monkey

Characteristics:

Original Species of Ab: Human

Original Format of Ab: IgG1

Purification: Protein A affinity purified

Purity: > 98 % as determined by SDS-PAGE

Endotoxin Level: Endotoxin is < 1.0 EU/mg as determined by the LAL method

Immunogen: Basiliximab was prepared by immunizing BALB/c mice with CTC 16 cells.

Isotype: IgG1 kappa

Application Details

Application Notes: Basiliximab is derived from the murine anti-Tac antibody. For the clinically used format, the variable regions from this antibody were grafted onto the sequence of the human IgG1κ constant regions. Basiliximab binding to CD25 competitively blocks the interaction of IL-2R with its ligand IL-2 on the surface of T cells. Blocking this interaction prevents T cell replication and T cell-mediated B cell activation. Basiliximab binding suppresses the immune system inhibits the pathway activating the cellular immune response to allograft rejection. IL-2 signalling suppression can additionally prevent acute graft-versus-host disease, autoimmune disorders and malignancies such as T cell leukemias (Binder et al, 2007). Basiliximab has also been used in FC, IF, IHC and WB studies, which enables the detection of CD25.

Comment:

NOT FOR THERAPEUTIC USE - This is a research-grade biosimilar. This is a chimeric antibody created for improved compatibility with existing reagents, assays and techniques.

Restrictions: For Research Use only

Handling

Concentration: 1 mg/mL

Buffer: PBS with 0.02 % Proclin 300.

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

Target Details for IL2RA (Basiliximab Biosimilar)

Target: IL2RA (Basiliximab Biosimilar)

Background: Interleukin-2 receptor subunit alpha, IL-2 receptor subunit alpha, IL-2R subunit alpha, IL-2-RA, IL2-RA, TAC antigen, p55, CD25.

UniProt: P01589